Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Smruthi Orgnics has informed that the company has received an ‘Attestation of Inspection’ from the European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, following the inspection conducted at its flagship API manufacturing facility, Unit II, Solapur, Maharashtra from 27 August 2025 to 29 August 2025. The attestation confirms compliance with the applicable European Good Manufacturing Practice (EU GMP) requirements under the CEP framework in respect of Amlodipine Besilate. A detailed disclosure in this regard is enclosed.
The above information is a part of company’s filings submitted to BSE.
